trial · primary record
Anlotinib Hydrochloride
Adenoid Cystic Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 76 |
| Primary completion | 2031-06-01 |
| Primary endpoint | 3-Year Progression-Free Survival |
| Registry ID | NCT07616141 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:26.503Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07616141
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.